ArticleExperimental and therapeutic medicine2022

Efficacy and safety of adjuvant therapy with PD‑1/PD‑L1 inhibitors in cancer.

Dun-Chang Mo et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.